Our results suggest that midostaurin, with its unique kinase profile and broad‐spectrum activity, could potentially be used clinically as a chemosensitizing agent for AML patients expressing either mutated or non‐mutated FLT3. Here, FLT3 is linked to acute myeloid leukemia.